Literature DB >> 1581909

Decreased expression of E-cadherin in the progression of rat prostatic cancer.

M J Bussemakers1, R J van Moorselaar, L A Giroldi, T Ichikawa, J T Isaacs, M Takeichi, F M Debruyne, J A Schalken.   

Abstract

Cadherins represent a family of Ca(2+)-dependent cell adhesion molecules involved in homotypic, homophilic cell-cell interactions. Recent studies have shown that the cadherins can play a role in invasive and metastatic behavior. Using the established Dunning R-3327 model system of serially transplantable rat prostate cancers, the expression of E- and P-cadherin in rat prostatic cancer was studied. Analysis within this system demonstrated that whereas E-cadherin was expressed in the normal rat prostate and the well- or moderately differentiated, noninvasive Dunning tumors, no expression, either at the mRNA or at the protein level, could be detected in the invasive sublines. Since not all invasive Dunning tumors studied have metastatic ability, these results suggest that a decreased expression of E-cadherin is correlated with invasive behavior rather than with metastatic ability. Recently, genetic instability occurred in an animal bearing the well differentiated, androgen-responsive, slow growing, nonmetastatic Dunning R-3327-H rat prostate cancer resulting in the progression to an anaplastic, androgen-independent, fast growing, highly metastatic state. This spontaneously arising tumor, termed the AT6 subline, in its original host was heterogeneously composed of both a well differentiated and an anaplastic population of cancer cells in which areas of squamous cell differentiation were occasionally observed. The original animal bearing this heterogeneous AT6 cancer developed multiple metastases, the lung metastases being heterogeneously composed of anaplastic and squamous cell populations. Cytogenetic analysis demonstrated that the lung metastases were derived from a specific subpopulation of cancer cells present in the original AT6 primary tumor. Immunohistochemical studies demonstrated that only the area of lung metastases displaying squamous morphology were positive for E-cadherin. In contrast, the anaplastic areas of the lung metastases and the metastases in other organs were E-cadherin negative. By the first passage of the AT6 tumor only the anaplastic cells were present and no detectable E-cadherin mRNA or protein was found in the primary tumor and metastatic deposits. These results suggest that a decreased expression of E-cadherin is associated with the progression of prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581909

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Survivin is a potential mediator of prostate cancer metastasis.

Authors:  Min Zhang; John J Coen; Yoshiyuki Suzuki; Michael R Siedow; Andrzej Niemierko; Li-Yan Khor; Alan Pollack; Yifen Zhang; Anthony L Zietman; William U Shipley; Arnab Chakravarti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

2.  Cadherins, steroids and cancer.

Authors:  O W Blaschuk; S B Munro; R Farookhi
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

Review 3.  Molecular genetics of prostate cancer: clinical applications.

Authors:  R A Morton; W B Isaacs
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

Review 4.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

5.  Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.

Authors:  Catarina Ferreira; João Lobo; Luís Antunes; Paula Lopes; Carmen Jerónimo; Rui Henrique
Journal:  Virchows Arch       Date:  2018-07-13       Impact factor: 4.064

6.  Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.

Authors:  Joanna Nightingale; Khurram S Chaudhary; Paul D Abel; Andrew P Stubbs; Hanna M Romanska; Stephen E Mitchell; Gordon W H Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

7.  The loss of E-cadherin mRNA transcripts in rat prostatic tumors is accompanied by increased expression of mRNA transcripts encoding fibronectin and its receptor.

Authors:  C D MacCalman; P Brodt; J D Doublet; R Jednak; M M Elhilali; M Bazinet; O W Blaschuk
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

8.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

Review 9.  Molecular mechanisms of metastasis in prostate cancer.

Authors:  Noel W Clarke; Claire A Hart; Mick D Brown
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

Review 10.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.